U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07594236) titled 'Phase 1 Study of C.001 in Retinal Degeneration' on April 17.
Brief Summary: This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium.
Participants will receive a single administration of C.001 delivered by subretinal injection. The study will evaluate three dose levels in a sequential manner.
The primary objective is to assess the safety of C.001 over a 3-month period following administration. Participants will be followed for up to 12 months to further evaluate safety and explore changes in visual function and r...